Investing.comCodex · 实盘不做把握 6/10
北京时间·🕒 发布 07-30 19:06:36时区推断·⟳ 抓取 07-30 19:08:20·⚡ 决策 07-31 02:46:23 +7h38m·88.7 天前
和黄医药披露2026年上半年收入基本持平、肿瘤免疫业务增长并维持全年指引
2026年上半年总收入2.783亿美元，几乎持平于上年同期2.777亿美元。
📄 原文Investing.com↗ 原文
HUTCHMED reports H1 2026 results with China sales rebound
U.S. launches fresh strikes on Iran as fighting intensifies across Middle East HONG KONG, SHANGHAI & FLORHAM PARK, N.J.…
不做 和黄医药（HCM.US）
财报类事件未体现明确超预期或指引上修，收入基本持平且美股已下跌，不做。
不做 和黄医药（00013.HK）
港股同一财报催化无明确正向surprise，且美股反应偏负面，方向与edge不足，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-30 · 扩散 medium · price-in 风险 medium ↗
消息传播链
- 报道披露H1收入2.783亿美元、归母净利1590万美元，并维持全年肿瘤免疫收入指引。市场反应:HCM.US当日跌6.06%，00013.HK当日跌0.06%。
关键理由
- 2026年上半年总收入2.783亿美元，几乎持平于上年同期2.777亿美元。
- 核心中国商业产品销售增长超过40%，肿瘤免疫合并收入从1.435亿美元增至1.623亿美元。
- 全年肿瘤免疫收入指引维持3.30亿至4.50亿美元，未形成上修指引的财报追多增量。
主要风险
- 归母净利润从4.55亿美元降至1590万美元，主要因去年包含4.163亿美元上海和黄药业股权出售收益，口径可比性弱。
- HCM.US当日下跌6.06%，港股00013.HK几乎持平，跨市场反应分歧显示短线方向不清。
工具调用 · 历史记录,结果未知(2 种)
- stock_quote · 结果未知
- normalize_ticker · 结果未知
原文全文
展开原文 · 1,986 字
U.S. launches fresh strikes on Iran as fighting intensifies across Middle East
HONG KONG, SHANGHAI & FLORHAM PARK, N.J. - HUTCHMED (NASDAQ:HCM; AIM:HCM; HKEX:13) reported financial results for the six months ended June 30, 2026, according to a press release statement issued today.
The company reported total consolidated revenue of $278.3 million for the first half of 2026, compared to $277.7 million in the same period last year. Net income attributable to HUTCHMED was $15.9 million, compared to $455.0 million in the first half of 2025, which included a $416.3 million gain from the divestment of 45% of Shanghai Hutchison Pharmaceuticals Limited.
In-market sales from key China commercial products increased over 40% compared to the first half of 2025. ELUNATE sales in China rose 41% to $60.8 million, while SULANDA sales increased 45% to $18.4 million. FRUZAQLA sales outside the U.S. grew approximately 70% to $68.9 million during the first half of 2026.
Oncology/Immunology consolidated revenue reached $162.3 million, up from $143.5 million in the prior year period. The company maintained a cash balance of $1.37 billion as of June 30, 2026.
The company received regulatory approval in China for ELUNATE in combination with sintilimab for second-line kidney cancer in May. China’s National Medical Products Administration accepted new drug applications for sovleplenib for warm autoimmune hemolytic anemia in April and for immune thrombocytopenia in February, both receiving priority review status.
HUTCHMED initiated clinical trials for three antibody-targeted therapy conjugate candidates: HMPL-A251 in December 2025, HMPL-A580 in March 2026, and received clinical trial application approval for HMPL-A830 in July 2026.
The company reiterated its full year 2026 guidance for Oncology/Immunology consolidated revenue in the range of $330 million to $450 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
HONG KONG, SHANGHAI & FLORHAM PARK, N.J. - HUTCHMED (NASDAQ:HCM; AIM:HCM; HKEX:13) reported financial results for the six months ended June 30, 2026, according to a press release statement issued today.
The company reported total consolidated revenue of $278.3 million for the first half of 2026, compared to $277.7 million in the same period last year. Net income attributable to HUTCHMED was $15.9 million, compared to $455.0 million in the first half of 2025, which included a $416.3 million gain from the divestment of 45% of Shanghai Hutchison Pharmaceuticals Limited.
In-market sales from key China commercial products increased over 40% compared to the first half of 2025. ELUNATE sales in China rose 41% to $60.8 million, while SULANDA sales increased 45% to $18.4 million. FRUZAQLA sales outside the U.S. grew approximately 70% to $68.9 million during the first half of 2026.
Oncology/Immunology consolidated revenue reached $162.3 million, up from $143.5 million in the prior year period. The company maintained a cash balance of $1.37 billion as of June 30, 2026.
The company received regulatory approval in China for ELUNATE in combination with sintilimab for second-line kidney cancer in May. China’s National Medical Products Administration accepted new drug applications for sovleplenib for warm autoimmune hemolytic anemia in April and for immune thrombocytopenia in February, both receiving priority review status.
HUTCHMED initiated clinical trials for three antibody-targeted therapy conjugate candidates: HMPL-A251 in December 2025, HMPL-A580 in March 2026, and received clinical trial application approval for HMPL-A830 in July 2026.
The company reiterated its full year 2026 guidance for Oncology/Immunology consolidated revenue in the range of $330 million to $450 million.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。